Showing 421 - 440 results of 45,002 for search '(( 5 ((ng decrease) OR (mean decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 1.02s Refine Results
  1. 421
  2. 422

    Decrease in cell viability by siRNA and miRNA dependent induction of DTA. by Liraz Harel (675561)

    Published 2014
    “…<p>U251 cells were transfected with the indicated construct (50 ng) with (A) or without (B) siRNAs (10pmol). …”
  3. 423
  4. 424
  5. 425
  6. 426
  7. 427
  8. 428

    Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart. by Craig Bolte (299486)

    Published 2013
    “…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”
  9. 429
  10. 430

    CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells. by Elif Aplak (7430123)

    Published 2020
    “…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
  11. 431

    SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
  12. 432
  13. 433
  14. 434
  15. 435
  16. 436

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  17. 437

    Decreasing ShcA expression enhances TGF-β-induced Smad signaling. by Baby Periyanayaki Muthusamy (838234)

    Published 2015
    “…(C) Subcellular localization of Smad2/3, assessed by immunofluorescence, in NMuMG or HaCaT cells, transfected with control or ShcA siRNA (siShc-a for NMuMG cells, siShc-c for HaCaT cells), in the absence of added TGF-β or in response to 2 ng/ml TGF-β for 60 min. (D, E) Decreasing ShcA expression, upon transfection of ShcA siRNA (siShc-a for NMuMG cells, siShc-c for HaCaT cells) but not control siRNA, enhances Smad3-mediated transcription, quantified by luciferase expression from a 4xSBE-luciferase reporter, in NMuMG (D) and HaCaT (E) cells, in the absence of or in response to 0.8 ng/ml TGF-β, or treated with SB431542, for 6 h. …”
  18. 438
  19. 439
  20. 440